NVCR - CIK 0001645113
NovoCure Ltd trades as NVCR and has a market capitalization of $1.94 B, making it the #2114 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $655.35M, up 8.3% from the prior year and net income of -$136.23M. This page tracks NovoCure Ltd through 1,138 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years NovoCure Ltd's revenue grew from $82.89M to $655.35M, a compound annual growth rate of 25.8%. Net profit margin expanded from -159.1% to -20.8% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Proxy materials | DEFA14A | 2026-05-21 |
| SCHEDULE 13G/A | - | 2026-05-08 |
| Major company event | 8-K | 2026-04-30 |
| Quarterly report | 10-Q | 2026-04-30 |
| SCHEDULE 13G | - | 2026-04-28 |
| Insider trade | 4 | 2026-04-28 |
| Major company event (amended) | 8-K/A | 2026-04-24 |
| Proxy materials | DEFA14A | 2026-04-20 |
Quarterly net revenues of $174 million , up 12% year-over-year, driven by global growth in Optune Gio®
The largest companies sharing NovoCure Ltd's SEC industry classification (surgical & medical instruments & apparatus).
NovoCure Ltd (NVCR) has a market capitalization of $1.94 B as of 2026-06-10, ranking #2114 among US-listed companies.
NovoCure Ltd reported revenue of $655.35M for fiscal year 2025, an increase of 8.3% year over year.
In its latest fiscal year NovoCure Ltd reported a net loss of $136.23M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.